Visit Flagship at SITC | Booth #818.November 8-12, 2022.Stop by our booth to meet our new CSO Tom Turi, Ph.D., and talk with us about how we can partner with you for end-to-end biomarker support. Come learn about our new services, and pick up a map of our favorite...
Events
UPCOMING EVENTS
- 14th World Clinical Biomarkers & Companion Diagnostics Summit | September 3-6, Boston, MA (Spotlight Partner)
- Spatial Biology in Drug Development | October, Boston, MA (Program Partner)
World CB & CDx 2022
Visit Flagship at World CB & CDx | Booth #4. Boston, MA | September 26-29, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support and see our latest data. Assay development and validation Clinical trial support...
AACR 2022
Visit Flagship at AACR | Booth #1554. April 8-13, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries. Assay...
Utilizing RNAscope in the clinic: Why you need image analysis to handle the complexity
Utilizing RNAscope in the clinic to handle complex analysis. RNAscope is rapidly becoming a solution for understanding complex biomarker challenges. The benefits and awareness of image analysis in the space of pathology have been widely discussed and rapidly growing....
Precision Patient Care: Seamless Optimization of Diagnoses, Companion Testing and Therapy Design
Technology Leads the Way to Precision Patient Care Digital transformation comes in many flavors. In pathology, it can be as simple as merely scanning pathology slides into whole slide images. However, it can also represent end-to-end digital pathology workflow...
Pathology Visions 2021
Pathology Visions 2021October 17-19, 2021Digital Pathology: The Future is Here is the theme of this year’s Digital Pathology Association annual conference, Pathology Visions 2021. #PathVisions21 featured a poster from Flagship’s CCO Meredith James on a novel approach...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Recognizing women leaders in biotechnology
The COVID-19 pandemic has highlighted the important need for cutting-edge life science research and technology to improve health outcomes. The Healthcare Technology Report recently announced, “The Top 25 Women Leaders in Biotechnology of 2021”, which is comprised of...
Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
Education and Early CareerJordyn received his Bachelor of Science in Community Health Sciences at the University of Nevada-Reno. Jordyn always wanted to be in the medical field, either in patient care or in medicine. According to an old yearbook, he actually wanted to...
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
PUBLICATIONS/POSTERS
Impact of adding Viagenpumatucel-L (HS-110) to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with Low Levels of Tumor Infiltrating Lymphocytes
Summary View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology conference. We cover image analysis of tumor infiltrating lymphocytes (TIL) and more.
Image Analysis-Based Identification and Quantification of Macrophages in PD-L1 (22C3) Stained NSCLC Tissue Sections Without Additional Macrophage-Specific Staining
ABSTRACT PD-L1 positivity in tumor-associated macrophages has been related to a favorable response to anti-PD-1 and PD-L1 targeted therapies. This concept has driven interest in specifically identifying macrophages in PD-L1 stained tissues, but pathologists often have...
Protein Tyrosine Kinase 7 (PTK7) Biomarker Analysis in Patients treated with PF-06647020, a PTK7 Antibody-Drug Conjugate (ADC), in a Phase I Dose Expansion Study
BACKGROUND F-06647020, an ADC comprising a humanized monoclonal antibody against PTK7, a cleavable valine-citrulline linker, and an auristatin payload, is being investigated in an ongoing Phase I clinical trial in patients with advanced solid tumors. We hypothesized...